Skip to main content

Table 5 Classifier performance for “HC vs. AD” using morphometric features only using ADNI and OASIS subjects

From: Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach

Experiment

Training set

Testing set

MCC

[CI: 95%]

BAC

[CI: 95%]

ROC AUC

[CI: 95%]

Sens

[CI: 95%]

Spec

[CI: 95%]

PPV (prevalence)

[CI: 95%]

NPV

(prevalence)

[CI: 95%]

PPV

(standard)

[CI: 95%]

NPV

(standard)

[CI: 95%]

TN

FP

FN

TP

MCC

p-value

(vs. w/ GT)

B1

ADNI MPRAGE

(N=194)

ADNI MPRAGE

(N=84)

0.814

[0.679;0.927]

90.8%

[84.1%;96.2%]

97.3%

[93.6%;99.6%]

94.9%

[87.2%;100.0%]

86.7%

[76.2%;95.5%]

81.7%

[69.6%;93.3%]

96.4%

[90.5%;100.0%]

87.7%

[78.6%;95.7%]

94.4%

[85.6%;100.0%]

39

6

2

37

0.974

B2

OASIS

(N=365)

OASIS

(N=152)

0.564

[0.344;0.771]

75.6%

[65.3%;87.2%]

94.1%

[89.7%;97.8%]

55.0%

[33.3%;77.3%]

96.2%

[92.5%;99.2%]

90.1%

[73.5%;98.4%]

77.3%

[68.9%;87.5%]

93.5%

[81.6%;99.0%]

68.1%

[58.1%;81.4%]

127

5

9

11

0.998

B3

OASIS

(N=517)

ADNI MPRAGE

(N=278)

0.722

[0.657;0.793]

84.3%

[80.3%;88.4%]

95.5%

[93.1%;97.5%]

70.5%

[63.0%;78.2%]

98.0%

[95.7%;100.0%]

95.7%

[90.2%;100.0%]

84.1%

[80.5%;88.0%]

97.2%

[93.6%;100.0%]

76.9%

[72.1%;82.1%]

146

3

38

91

0.623

B4

ADNI MPRAGE

(N=278)

OASIS

(N=517)

0.641

[0.551;0.733]

87.2%

[82.4%;97.0%]

94.3%

[91.3%;97.0%]

83.6%

[74.6%;91.7%]

90.9%

[88.3%;93.5%]

85.2%

[80.0%;89.8%]

89.9%

[84.7%;94.7%]

90.2%

[86.4%;93.4%]

84.7%

[77.7%;91.8%]

409

41

11

56

0.265

B5

ADNI MPRAGE

and

OASIS

(N=295)

ADNI MPRAGE

and

OASIS

(N=127)

0.811

[0.701;0.906]

90.6%

[85.3%;95.5%]

97.4%

[94.9%;99.3%]

91.5%

[83.6%;98.3%]

89.7%

[81.8%;96.2%]

84.8%

[74.2%;94.2%]

94.4%

[88.9%;98.9%]

89.9%

[82.1%;96.3%]

91.4%

[83.3%;98.3%]

61

7

5

54

0.383

  1. MCC p-value refers to the p-value for the MCC metric for the comparison with the equivalent classifier (i.e., same training and test sets) with morphometric and GT features. PPV/NPV “prevalence” are calculated with an AD prevalence of 38.5% (this corresponds to the prevalence of AD relative to HC based on prevalence estimates from the first visit in the clinical setting of 42.0% for HC and 26.3% for AD) [48]. PPV/NPV “standard” are calculated with a prevalence of 50% to allow for comparison with other studies
  2. CI confidence interval, MCC Matthew’s correlation coefficient, ROC AUC area under the receiver operating characteristic curve, BAC balanced accuracy, Sens sensitivity, Spec specificity, PPV positive predict value, NPV negative predictive value, TN true negatives, FP false positives, FN false negatives, TP true positives. The most global classifier is highlighted